RichardEldonRoyalMD
General Surgery • Portland, MESurgical Oncology (Other than Breast)
Professor of Surgery, MD Anderson Cancer Ctr., Univ. of Texas
Dr. Royal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
887 Congress St
Portland, ME 04102Phone+1 207-774-6368Fax+1 207-774-9388
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Complex General Surgical Oncology, 2001 - 2003
University of MarylandResidency, Surgery, 1997 - 2000
University of RochesterFellowship, Surgery, 1994 - 1997
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1993 - 1994
Cincinnati Children's Hospital Medical CenterFellowship, Research - Pediatric Surgery, 1991 - 1993
Wellspan Health/York HospitalResidency, Surgery, 1988 - 1991
Oregon Health and Science University School of MedicineClass of 1988
Certifications & Licensure
ME State Medical License 2019 - 2026
OR State Medical License 2019 - 2025
TX State Medical License 2001 - 2021
OH State Medical License 1991 - 2002
PA State Medical License 1990 - 1992- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial Start of enrollment: 2006 Apr 01
- Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer Start of enrollment: 2007 Sep 01
- Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist Start of enrollment: 2010 May 20
- Join now to see all
Publications & Presentations
PubMed
- 1058 citationsGene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Laura A. Johnson, Richard A. Morgan, Mark E. Dudley, Lydie Cassard, James Chih-Hsin Yang
Blood. 2009-07-16 - 748 citationsAutoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Peter Attia, Giao Q. Phan, Ajay V. Maker, Michael R. Robinson, Martha Quezado
Journal of Clinical Oncology. 2005-09-01 - 1218 citationsAdoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic MelanomaMark E. Dudley, John R. Wunderlich, James Chih-Hsin Yang, Richard M. Sherry, Suzanne L. Topalian
Journal of Clinical Oncology. 2005-04-01
Journal Articles
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
Press Mentions
Staying Positive in the Face of UncertaintyNovember 30th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
